ArticleInternational journal of dentistry2026
Evaluation of GCF Adiponectin and Resistin Expression Level as an Indicator in Periodontal Staging and Grading After Periodontal Therapy in Class III Obese Patients.
Article in International journal of dentistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of GCF Adiponectin and Resistin Expression Level as an Indicator in Periodontal Staging and Grading After Periodontal Therapy in Class III Obese Patients.International journal of dentistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The current trial aimed to assess the effects of phase I periodontal therapy on gingival crevicular fluid (GCF) adiponectin and resistin levels in obese individuals with varying stages and grades of periodontitis. The feasibility of using adiponectin and resistin in a periodontitis staging and grading classification system was being evaluated. Materials and Methods: This prospective clinical study was carried out on 60 class Ⅲ obese periodontitis patients who were divided equally into group І, first stage, grade B periodontitis; group Ⅱ, second stage, grade B periodontitis; group Ⅲ, third stage, grade B periodontitis; and group Ⅳ, fourth stage, grade C periodontitis. Body mass index (BMI), HbA1c, and periodontal indices were assessed, and GCF was collected and analyzed for adiponectin and resistin, before and 3 months after treatment. Results: A positive correlation was observed between BMI/HbA1c and periodontal disease stages. After periodontal therapy, adiponectin and resistin levels were obviously affected. In group Ⅲ resistin decreases from 25.68 ± 0.89 to 14.68 ± 1.54 ng/mL, adiponectin rose from 155.8 ± 39.7 to 435.8 ± 49.2 ng/mL. In group Ⅳ, resistin decreased from 53.2 ± 1.1 to 20.3 ± 2.03 ng/mL, and adiponectin increased from 104.41 ± 8.87 to 543.21 ± 36.81 ng/mL. There were no statistically significant correlations between clinical attachment level (CAL) and adiponectin/resistin. In grade B periodontitis, resistin decreased from 17.25 ± 6.1 to 13.5 ± 1.39 ng/mL after periodontal therapy. Adiponectin rose from 257.27 ± 84.26 to 355.61 ± 72.4 ng/mL. In grade C periodontitis, resistin expression was lower, from 53.2 ± 1.1 to 20.37 ± 2.03 ng/mL, whereas adiponectin was elevated from 104.41 ± 8.8 to 543.21 ± 36.81 ng/mL after 3 months of periodontal control treatment. Conclusion: Adiponectin and resistin were significantly affected after periodontal therapy, especially in stage 3 and stage 4 periodontitis. Adiponectin can be used as an intermediary for periodontitis grading.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.